Growing Initiatives to Increase Patient Awareness to Bode Well for Global Lupus Nephritis Market

Published Date : Jun 12, 2017

ALBANY, New York, June 12, 2017 – The increasing prevalence of lupus nephritis is perhaps the main factor driving the global market for the same. In a report recently added to the vast repository of, the leading factors driving and restricting the growth and expansion of the lupus nephritis market have been studied and projections about its future have been assessed with the help of the latest industry tools. The report is titled “Global Lupus Nephritis Market: Industry Analysis & Outlook (2021-2030)”.

According to the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, lupus nephritis – a type of kidney disease – is a disorder that affects the immune system. This autoimmune disease is caused by systemic lupus erythematosus (SLE). The Lupus Research Institute in the U.S. states that over 1.5 million Americans are affected by lupus nephritis. However, awareness about this disease is still low in the country and around the world. Nevertheless, research institutes, healthcare companies, and government organizations are all working to spread awareness about lupus nephritis, thereby giving this market a significant boost.

The major factors boosting the growth of the worldwide market for lupus nephritis have been discussed at length in the report and the various trends and developments influencing its growth in the present as well as in the coming years have also been evaluated. Apart from this, the key challenges that threaten to impede the expansion of the lupus nephritis market have been highlighted.

For Sample Copy, click here:

As per the findings presented in the report, the global lupus nephritis market is fueled by increasing healthcare expenditure, growing prevalence of lupus nephritis, a rise in African-American population in certain parts of the world, and rapid economic expansion in many countries. In addition to this, increasing public awareness about the disease, a surge in research grants and initiatives, and a rising number of drugs in the pipeline are a few prominent trends that are likely to have a positive impact on the overall lupus nephritis market. On the downside, however, high costs of the treatment of this disease, the associated risks of the drugs, and strict regulatory norms will limit the growth of this market.

Geographically, the lupus nephritis market has been segmented into Japan, Europe, and the U.S. The patient population forecast for each regional market and its forecast in terms of value has been provided. Both the U.S. and Europe are prominent markets owing to the growing prevalence of lupus nephritis among the population here. These markets are also driven by increasing research and development activities in the field and the presence of advanced and sophisticated healthcare infrastructure. The introduction of biologics has resulted in the rising demand for treatment options for various ailments and diseases in Asia Pacific, especially boosting the lupus nephritis market in Japan.

The report profiles the top five companies in the global lupus nephritis market, carefully studying their business strategies and offering a detailed overview of the firms’ business and finances. The players covered in the report are GlaxoSmithKline Plc., Bristol-Myers Squibb, Roche Holding AG, AstraZeneca, and Aurinia Pharmaceuticals Inc.

To order report Call Toll Free: 866-997-4948 or send an email on